Citations

Showing 10 of 108094 citations.

Do recent reports about the adverse effects of proton pump inhibitors change providers’ prescription practice?
Al-Qaisi, Mohanad, Kahn, Allon , Burdick, George E., Vela, Marcelo F. , Ramirez, Francisco C. , Crowell, Michael D. , Kahn, Allon

Mayo Clinic

Diseases of the Esophagus | June 4, 2018 | Volume: 31 | Issue: 12 | Pages: No page available

10.1093/dote/doy042 | PMID 29873678 Get It

Caloric Intake, Aging, and Mild Cognitive Impairment: A Population-Based Study
Geda, Yonas E. , Ragossnig, Marion, Roberts, Lewis A., Roberts, Rosebud O., Christianson, Teresa J., Levine, James A. , Sochor, Ondřej , Tangalos, Eric G., Petersen, Ronald C. , Geda, Yonas E , Pankratz, V. Shane , Mielke, Michelle M. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 34 | Issue: 2 | Pages: 501-507

10.3233/jad-121270 | PMID 23234878 Get It

Molecular Testing in Thyroid Cancer
Gharib, Hossein

Mayo Clinic

US Endocrinology | June 4, 2018 | Volume: 14 | Issue: 1 | Pages: 22

10.17925/use.2018.14.1.22 Get It

It has been estimated that two-thirds of the world population have thyroid nodules, 1 and their incidence increases with age. 2 While most are benign, 1 the incidence of thyroid cancer has increased substantially worldwide over the last four decades. 3 Therefore, there is a need for reliable methods of thyroid nodule evaluation. Fine-needle biopsy with cytologic evaluation remains the standard diagnostic test to distinguish benign from malignant thyroid nodules but has a number of limitations, including its inability to identify aggressive tumors. 4 In an expert interview, Dr Hossein Gharib of the Mayo Clinic College of Medicine, Rochester, MN, discusses the need for molecular testing in thyroid cancer.
Management of a late breast implant rupture in the setting of previous radiation
Molinar, Vanessa E., Sabbagh, M. Diya , Manrique, Oscar J. , Sabbagh, Mohamed Diya

Mayo Clinic

BMJ Case Reports | June 4, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2018-224578

10.1136/bcr-2018-224578 | PMID 29866685 Get It

Management of ruptured breast implants is scarcely discussed in the literature, especially in the setting of previous breast cancer and radiation. The authors present an uncommon presentation of late breast implant rupture with seroma and history of prior radiation. It is important to acknowledge the increased risk of wound healing complications in patients who are several years’ postradiation therapy for breast cancer and should be an important factor when discussing treatment options with the patient.
Characteristics of TBS-Extractable Hyperphosphorylated Tau Species: Aggregation Intermediates in rTg4510 Mouse Brain
DeTure, Michael , Ren, Yan, Ebrahim, Abdul-Shukkur, Kang, Dongcheul, Volbracht, Christiane , Pedersen, Jan T., Dickson, Dennis W. , Yen, Shu‐Hui, Lewis, Jada , Dickson, Dennis W , Sahara, Naruhiko , Knight, Joshua A.

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 33 | Issue: 1 | Pages: 249-263

10.3233/jad-2012-121093 | PMID 22941973 Get It

Treatment of Major Depressive Disorder in Pediatric Populations
Neavin, Drew , Joyce, Jeremiah B. , Swintak, Cosima, Neavin, Drew R, Joyce, Jeremiah , Neavin, Drew R

Mayo Clinic

Diseases | June 4, 2018 | Volume: 6 | Issue: 2 | Pages: 48

10.3390/diseases6020048 | PMID 29866991 Get It

Major depressive disorder (MDD) is a severe illness that afflicts about 16.6% of people over their lifetime. MDD is highly correlated with suicidality, and often first presents in adolescence. Unfortunately, many pediatric patients suffering from MDD go undiagnosed, and current evidence-based treatment options in the U.S. are limited to psychotherapy and two selective serotonin reuptake inhibitors approved by the United States Food and Drug Administration. Molecular mechanisms have been shown to play a role in MDD pathogenesis, progression, and response to medication, yet few studies have explored the role of these pathways in pediatric MDD. In this review, we outline the gravity and importance of MDD in pediatric patients, some challenges in diagnosis and treatment, current treatments available for pediatric patients, and research to investigate differences between pediatric and adult MDD. We hope that this review will provide an outline of the current understanding and treatment of MDD in pediatric patients, and provide thoughtful insights for future work that could advance our understanding of MDD in pediatric populations, and also identify new therapeutic strategies.
Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension
Enderby, Cher Y. , Burger, Charles D.

Mayo Clinic

Therapeutic Advances in Chronic Disease | June 4, 2018 | Volume: 9 | Issue: 9 | Pages: 171-177

10.1177/2040622318779749 | PMID 30181846 Get It

Background: Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary arterial hypertension. Inhaled treprostinil avoids issues with continuous infusion prostanoids. This study describes a single institutional experience with inhaled treprostinil. Methods: This was a retrospective review of group 1 pulmonary arterial hypertension patients receiving inhaled treprostinil from July 2009 through September 2015. Patient demographics, vital signs, prognostic indicators, pulmonary arterial hypertension assessments, treprostinil dosing, pulmonary arterial hypertension medications, and physician assessment were collected. Prognostic indicators and the physician assessment were used to assess treatment response. A modified Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) risk score was calculated prior to and after initiation of inhaled treprostinil. Results: The mean time on inhaled treprostinil for the 16 patients was 21 ± 17 months. A total of 31% discontinued treatment. The New York Heart Association Functional Class, right ventricular size, and right ventricular function improved after inhaled treprostinil. Directional improvement in B-type natriuretic peptide, 6-minute walk distance, right arterial pressure and mean pulmonary artery pressure were also observed. The mean modified REVEAL risk score (RRS) was 7 ± 3 at baseline. The RRS decreased in 7 of the 11 patients that improved and remained stable in 2 patients. Conclusion: The majority of patients in this consecutive series receiving inhaled treprostinil tolerated treatment. Most patients remained on therapy for over 12 months. Clinical assessments of disease severity all changed directionally toward improvement and the overall risk assessment was improved or stable in 56% by the RRS.
Previous foot injuries associated with a greater likelihood of Achilles tendon ruptures in professional American football players
Krill, Michael K. , Hoffman, Joshua, Hodax, Johnathan D., Owens, Brett D. , Hewett, Timothy E. , Yang, JaeWon

Mayo Clinic

The Physician and Sportsmedicine | June 4, 2018 | Volume: 46 | Issue: 3 | Pages: 342-348

10.1080/00913847.2018.1482188 | PMID 29860909 Get It

Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type
Whitwell, Jennifer L., Kantarci, Kejal , Weigand, Stephen D. , Lundt, Emily S. , Gunter, Jeffrey L. , Spychalla, Anthony J., Drubach, Daniel A., Petersen, Ronald C. , Lowe, Val J. , Josephs, Keith A. , Strand, Edythe A. , Kantarci, Kejal , Whitwell, Jennifer , Duffy, Joseph R. , Machulda, Mary M. , Jack, Clifford R. , Lundt, Emily S

Mayo Clinic

Journal of Alzheimer’s Disease | June 4, 2018 | Volume: 45 | Issue: 4 | Pages: 1109-1117

10.3233/jad-142628 | PMID 25649655 Get It

Background: Microbleeds in the brain have been shown to occur in Alzheimer’s disease (AD), affecting approximately a third of subjects that present with typical dementia of the Alzheimer’s type (DAT). However, little is known about the frequency or distribution of microbleeds in subjects with AD that present with atypical clinical presentations. Objective: To determine whether the frequency and regional distribution of microbleeds in atypical AD differs from that observed in subjects with DAT, and to determine whether microbleeds in atypical AD are associated with age, demographics, or cognitive impairment. Methods: Fifty-five subjects with amyloid-β deposition on Pittsburgh compound B (PiB) PET who presented with predominant language (n = 37) or visuospatial/perceptual (n = 18) deficits underwent T2*weighted MRI. These subjects were compared to 41 PiB-positive subjects with DAT. Microbleeds were identified and assigned a lobar location. Results: The proportion of subjects with microbleeds did not differ between atypical AD (42%) and DAT (32%). However, atypical AD had larger numbers of microbleeds than DAT. In addition, the topographic distribution of microbleeds differed between atypical AD and DAT, with atypical AD showing the highest density of microbleeds in the frontal lobes. Among atypical AD, number of microbleeds was associated with age, but not gender or cognition. Microbleeds were more common in subjects with language (51%) versus visuospatial/perceptual deficits (22%). Conclusions: Microbleeds are relatively common in both DAT and atypical AD, although atypical AD subjects appear to be at particular risk for developing large numbers of microbleeds and for developing microbleeds in the frontal lobe.
Atlas-Based Diffusion Tensor Imaging Correlates of Executive Function
Nowrangi, Milap A., Okonkwo, Ozioma C. , Lyketsos, Constantine G. , Oishi, Kenichi , Mori, Susumu , Albert, Marilyn , Mielke, Michelle M. , Mielke, Michelle M

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 44 | Issue: 2 | Pages: 585-598

10.3233/jad-141937 | PMID 25318544 Get It